Patent intelligence · PT
PT 2114927
PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE
PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE
Patent details — PT 2114927
- Jurisdiction
- PT
- Status
- granted
- Grant date
- Nov 24, 2017
- Expiration
- Nov 19, 2037
- Applicant
- BIAL-PORTELA & Cª S A [PT]
- CPC classes
- A61P/904, A61P/912
Quick answer
PT 2114927 (PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Nov 24, 2017. Expires Nov 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL-PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/904, A61P/912
More from BIAL-PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2114927?
PT 2114927 (PROCESS FOR THE PREPARATION OF (R)-5-(2-AMINOETHYL)-1-(6,8-DIFLUOROCHROMAN-3-YL)-1,3-DIHYDROIMIDAZOLE-2-THIONE) is held by BIAL-PORTELA & Cª S A [PT]. Status: granted. Granted Nov 24, 2017. Expires Nov 19, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns PT 2114927?
BIAL-PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does PT 2114927 expire?
Our index shows an expiration date of Nov 19, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.